This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Stocks Gain as Weak Economic Data Bolsters Fed Stimulus

Stock quotes in this article: ^DJI, ^GSPC, ^IXIC, LRCX, INTC, MRK, BMY

NEW YORK ( TheStreet) -- U.S. stocks gained Monday on prospects that worse-than-expected manufacturing data will prompt the Federal Reserve to continue its stimulus program to bolster the economic recovery.

The S&P 500 advanced 0.6% to close at 1,640.39.

The Institute for Supply Management reported that the ISM manufacturing survey for May fell to 49 from 50.7 in April; economists were expecting levels to remain at 50.7. At the same time, the Census Bureau said that constructing spending rose by a less than expected 0.4% in April after dipping by an upwardly-revised 0.8% in March. Economists, on average, had estimated a construction spending increase of 0.8% in April.

Markit reported earlier Monday that the final estimate on the U.S. Manufacturing Purchasing Managers Index for May was 52.3, modestly higher than the final April reading of 52.1.

"We can now say with even more confidence that there is literally zero chance the Fed announces any adjustments to its QE program in June and along with the decline in inflation measures, the risks are growing that our September call looks optimistic," Dan Greenhaus, chief global strategist at BTIG in New York commented in a note after the ISM manufacturing report.

The Dow Jones Industrial Average gained 0.9% to 15,254.03 while the Nasdaq rose 0.3% to 3,465.37.

Intel (INTC) jumped 4% to $25.24 after the chipmaker was raised to "outperform" from "market perform" by FBR Capital analysts, who wrote that the company exhibits strong growth potential despite the sharp deterioration in the PC market.

Bristol-Myers Squibb (BMY) gained 3.4% to $47.59 while Merck (MRK) added 3.8% to $48.45. The anti-PD-1 therapies from Bristol-Myers Squibb and Merck stole the show during the weekend's American Society of Clinical Oncology (ASCO) annual meeting. Merck was able to feature stunningly good results, while Bristol-Myers continued to show that its Nivolumab has the potential to be a blockbuster melanoma drug, but even more enticing is the potential for the drug to re-write the lung cancer treatment playbook.

Lam Research (LRCX) advanced 3.2% to $48.25 after Needham analysts raised their price target on the supplier of equipment to the semiconductor industry to $60 from $53, anticipating that the company is poised for stronger revenue growth than its competitors.

Written by Andrea Tse in New York

>To contact the writer of this article, click here: Andrea Tse.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs